Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
BRAF-MEK-remming bij nieuw gediagnosticeerd papillair craniofaryngeoom
nov 2023 | Neuro-oncologie